tetano
Editor, Senior Moderator
Oncologist
. 2023 Mar 27;oyad067.
doi: 10.1093/oncolo/oyad067. Online ahead of print.
Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis
Luis Meza[SUP] 1 [/SUP], Zeynep Zengin[SUP] 1 [/SUP], Sabrina Salgia[SUP] 1 [/SUP], Jasnoor Malhotra[SUP] 1 [/SUP], Ewa Karczewska[SUP] 2 [/SUP], Tanya Dorff[SUP] 1 [/SUP], Abhishek Tripathi[SUP] 1 [/SUP], Jennifer Ely[SUP] 3 [/SUP], Erin Kelley[SUP] 3 [/SUP], Heather Mead[SUP] 3 [/SUP], Jo Ann Hsu[SUP] 1 [/SUP], Nazli Dizman[SUP] 1 4 [/SUP], Nicholas Salgia[SUP] 1 [/SUP], Neal Chawla[SUP] 1 [/SUP], Alex Chehrazi-Raffle[SUP] 1 [/SUP], Ramya Muddasani[SUP] 1 [/SUP], Ameish Govindarajan[SUP] 1 [/SUP], Adam Rock[SUP] 1 [/SUP], Sandy Liu[SUP] 1 [/SUP], Ravi Salgia[SUP] 1 [/SUP], Jeffrey Trent[SUP] 5 [/SUP], John Altin[SUP] 3 [/SUP], Sumanta K Pal[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have had a transformative impact on morbidity and mortality. However, the long-term impact of vaccination on patients with genitourinary cancers is currently unknown.
Materials and methods: This study aimed to assess seroconversion rates in patients with genitourinary cancers receiving COVID-19 vaccination. Patients with prostate cancer, renal cell carcinoma, or urothelial cancer who had not been vaccinated for COVID-19 were included. Blood samples were obtained at baseline and after 2, 6, and 12 months of one dose of an FDA-approved COVID-19 vaccine. Antibody titer analysis was performed using the SCoV-2 Detect IgG ELISA assay, and the results were reported as immune status ratio (ISR). A paired t-test was used for comparison of ISR values between timepoints. In addition, T-cell receptor (TCR) sequencing was performed to assess for differences in TCR repertoire 2 months after vaccination.
Results: Out of 133 patients enrolled, 98 baseline blood samples were collected. At 2-, 6-, and 12-month time points 98, 70, and 50 samples were collected, respectively. Median age was 67 (IQR, 62-75), with the majority of patients diagnosed with prostate (55.1%) or renal cell carcinoma (41.8%). Compared to baseline (0.24 [95% CI, 0.19-0.31]) a significant increase in the geometric mean ISR values was observed at the 2-month timepoint (5.59 [4.76-6.55]) (P < .001). However, at the 6-month timepoint, a significant decrease in the ISR values was observed (4.66 [95% CI, 4.04-5.38]; P < .0001). Notably, at the 12-month timepoint, the addition of a booster dose resulted in an absolute increase in the ISR values compared to those who did not receive a booster dose (P = .04).
Conclusions: Only a minority of patients with genitourinary cancers did not ultimately achieve satisfactory seroconversion after receiving commercial COVID-19 vaccination. Cancer type or treatment rendered did not appear to affect the immune response mounted after vaccination.
Keywords: COVID-19 vaccine; genitourinary cancer; immune response.
. 2023 Mar 27;oyad067.
doi: 10.1093/oncolo/oyad067. Online ahead of print.
Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis
Luis Meza[SUP] 1 [/SUP], Zeynep Zengin[SUP] 1 [/SUP], Sabrina Salgia[SUP] 1 [/SUP], Jasnoor Malhotra[SUP] 1 [/SUP], Ewa Karczewska[SUP] 2 [/SUP], Tanya Dorff[SUP] 1 [/SUP], Abhishek Tripathi[SUP] 1 [/SUP], Jennifer Ely[SUP] 3 [/SUP], Erin Kelley[SUP] 3 [/SUP], Heather Mead[SUP] 3 [/SUP], Jo Ann Hsu[SUP] 1 [/SUP], Nazli Dizman[SUP] 1 4 [/SUP], Nicholas Salgia[SUP] 1 [/SUP], Neal Chawla[SUP] 1 [/SUP], Alex Chehrazi-Raffle[SUP] 1 [/SUP], Ramya Muddasani[SUP] 1 [/SUP], Ameish Govindarajan[SUP] 1 [/SUP], Adam Rock[SUP] 1 [/SUP], Sandy Liu[SUP] 1 [/SUP], Ravi Salgia[SUP] 1 [/SUP], Jeffrey Trent[SUP] 5 [/SUP], John Altin[SUP] 3 [/SUP], Sumanta K Pal[SUP] 1 [/SUP]
Affiliations
- PMID: 36971500
- DOI: 10.1093/oncolo/oyad067
Abstract
Background: Vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have had a transformative impact on morbidity and mortality. However, the long-term impact of vaccination on patients with genitourinary cancers is currently unknown.
Materials and methods: This study aimed to assess seroconversion rates in patients with genitourinary cancers receiving COVID-19 vaccination. Patients with prostate cancer, renal cell carcinoma, or urothelial cancer who had not been vaccinated for COVID-19 were included. Blood samples were obtained at baseline and after 2, 6, and 12 months of one dose of an FDA-approved COVID-19 vaccine. Antibody titer analysis was performed using the SCoV-2 Detect IgG ELISA assay, and the results were reported as immune status ratio (ISR). A paired t-test was used for comparison of ISR values between timepoints. In addition, T-cell receptor (TCR) sequencing was performed to assess for differences in TCR repertoire 2 months after vaccination.
Results: Out of 133 patients enrolled, 98 baseline blood samples were collected. At 2-, 6-, and 12-month time points 98, 70, and 50 samples were collected, respectively. Median age was 67 (IQR, 62-75), with the majority of patients diagnosed with prostate (55.1%) or renal cell carcinoma (41.8%). Compared to baseline (0.24 [95% CI, 0.19-0.31]) a significant increase in the geometric mean ISR values was observed at the 2-month timepoint (5.59 [4.76-6.55]) (P < .001). However, at the 6-month timepoint, a significant decrease in the ISR values was observed (4.66 [95% CI, 4.04-5.38]; P < .0001). Notably, at the 12-month timepoint, the addition of a booster dose resulted in an absolute increase in the ISR values compared to those who did not receive a booster dose (P = .04).
Conclusions: Only a minority of patients with genitourinary cancers did not ultimately achieve satisfactory seroconversion after receiving commercial COVID-19 vaccination. Cancer type or treatment rendered did not appear to affect the immune response mounted after vaccination.
Keywords: COVID-19 vaccine; genitourinary cancer; immune response.